Daniel Hägerstrand

Daniel Hägerstrand

Auto-generated profile, based on publicly available information

Daniel Hägerstrand

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ESElin Sjöberg
Elin Sjöberg
MMMax Meyrath
Max Meyrath
LMLaura Milde
Laura Milde
MHMercedes Herrera
Mercedes Herrera
JLJohn Lövrot
John Lövrot
AÖArne Östman
Arne Östman
Purpose: Fibroblasts expressing the orphan chemokine CXCL14 have been previously shown to associate with poor breast cancer prognosis and promote cancer growth. This study explores the mechanism underlying the poor survival-associations of stromal CXCL14. Experimental Design: Tumor cell EMT, invasion and metastasis were studied in in vitroand in vivomodels together with fibroblasts overexpressing CXCL14. An approach for CXCL14-receptor identification included loss-of-function studies followed by molecular and functional endpoints. The clinical relevance was further explored in publicly available gene expression datasets. Results: CXCL14-fibroblasts stimulated breast cancer EMT, migration and invasion in breast cancer cells and in a xenograft model. Furthermore, tumor cells primed by CXCL14-fibroblasts displayed enhanced lung colonization after tail-vein injection. By loss-of function experiments the atypical GPCR ACKR2 was identified to mediate CXCL14-stimulated responses. Down-regulation of ACKR2, or CXCL14-induced NOS1, attenuated the pro-EMT and migratory capacity. CXCL14/ACKR2 expression correlated with EMT and survival in gene expression data sets. Conclusions: Collectively, findings imply an autocrine fibroblast CXCL14/ACKR2 pathway as a clinically relevant stimulator of EMT, tumor cell invasion and metastasis. The study also identifies ACKR2 as a novel mediator for CXCL14 function and thereby defines a pathway with drug target potential.

22 September 2011 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DHDaniel Hägerstrand
Daniel Hägerstrand
XHXiaobing He
Xiaobing He
MLMaja Bradic Lindh
Maja Bradic Lindh
SHSaskia Hoefs
Saskia Hoefs
GHGöran Hesselager
Göran Hesselager
MNMonica Nistér
Monica Nistér
Putative cancer stem cells have been identified in glioblastomas and are associated with radio- and chemo-resistance. Further knowledge about these cells is thus highly warranted for the development of better glioblastoma therapies. Gene expression analyses of 11 high-grade glioma cultures identified 2 subsets, designated type A and type B cultures. The type A cultures displayed high expression of CXCR4, SOX2, EAAT1, and GFAP and low expression of CNP, PDGFRB, CXCL12, and extracellular matrix proteins. Clinical significance of the 2 types was indicated by the expression of type A– and type B–defining genes in different clinical glioblastoma samples. Classification of glioblastomas with type A– and type B–defining genes generated 2 groups of tumors composed predominantly of the classical, neural, and/or proneural subsets and the mesenchymal subset, respectively. Furthermore, tumors with EGFR mutations were enriched in the group of type A samples. Type A cultures possessed a higher capacity to form xenograft tumors and neurospheres and displayed low or no sensitivity to monotreatment with PDGF- and IGF-1–receptor inhibitors but were efficiently growth inhibited by combination treatment with low doses of these 2 inhibitors. Furthermore, siRNA-induced downregulation of SOX2 reduced sphere formation of type A cultures, decreased expression of type A–defining genes, and conferred sensitivity to monotreatment with PDGF- and IGF-1–receptor inhibitors. The present study thus describes a tumor- and neurosphere-forming SOX2-dependent subset of glioblastoma cultures characterized by a gene expression signature similar to that of the recently described classical, proneural, and/or neural subsets of glioblastoma. The findings that resistance to PDGF- and IGF-1–receptor inhibitors is related to SOX2 expression and can be overcome by combination treatment should be considered in ongoing efforts to develop novel stem cell–targeting therapies.

20 March 2006 in Oncogene
Verified
Journal Article
Closed access
DHD Hägerstrand
D Hägerstrand
GHG Hesselager
G Hesselager
SAS Achterberg
S Achterberg
UBU Wickenberg Bolin
U Wickenberg Bolin
MKM Kowanetz
M Kowanetz
AÖArne Östman
Arne Östman

1 September 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
DHDaniel Hagerstrand
Daniel Hagerstrand
ATAlexander Tong
Alexander Tong
SSSteven E. Schumacher
Steven E. Schumacher
NINina Ilic
Nina Ilic
RSRhine R. Shen
Rhine R. Shen
WHWilliam C. Hahn
William C. Hahn
3q26 is frequently amplified in several cancer types with a common amplified region containing 20 genes. To identify cancer driver genes in this region, we interrogated the function of each of these genes by loss- and gain-of-function genetic screens. Specifically, we found that TLOC1 (SEC62) was selectively required for the proliferation of cell lines with 3q26 amplification. Increased TLOC1 expression induced anchorage-independent growth, and a second 3q26 gene, SKIL (SNON), facilitated cell invasion in immortalized human mammary epithelial cells. Expression of both TLOC1 and SKIL induced subcutaneous tumor growth. Proteomic studies showed that TLOC1 binds to DDX3X, which is essential for TLOC1-induced transformation and affected protein translation. SKIL induced invasion through upregulation of SLUG (SNAI2) expression. Together, these studies identify TLOC1 and SKIL as driver genes at 3q26 and more broadly suggest that cooperating genes may be coamplified in other regions with somatic copy number gain. Significance: These studies identify TLOC1 and SKIL as driver genes in 3q26. These observations provide evidence that regions of somatic copy number gain may harbor cooperating genes of different but complementary functions. Cancer Discov; 3(9); 1044–57. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 953

23 December 2013 in Oncogene
Verified
Journal Article
Open access
PDF file
RSR R Shen
R R Shen
AZA Y Zhou
A Y Zhou
EKE Kim
E Kim
JOJ T O'Connell
J T O'Connell
DHD Hagerstrand
D Hagerstrand
WHW C Hahn
W C Hahn
Aberrant nuclear factor (NF)-κB activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-κB pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here, using patient tumors and cancer cell lines, we identify the NF-κB regulator, TRAF2 (tumor necrosis factor (TNF) receptor-associated factor 2), as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-κB activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-κB for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together, these observations identify TRAF2 as a frequently amplified oncogene.

20 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LPLinda Pudelko
Linda Pudelko
PRPegah Rouhi
Pegah Rouhi
KSKumar Sanjiv
Kumar Sanjiv
HGHelge Gad
Helge Gad
CKChristina Kalderén
Christina Kalderén
LBLars Bräutigam
Lars Bräutigam
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with poor prognosis. Cancer cells are characterized by a specific redox environment that adjusts metabolism to its specific needs and allows the tumor to grow and metastasize. As a consequence, cancer cells and especially GBM cells suffer from elevated oxidative pressure which requires antioxidant-defense and other sanitation enzymes to be upregulated. MTH1, which degrades oxidized nucleotides, is one of these defense enzymes and represents a promising cancer target. We found MTH1 expression levels elevated and correlated with GBM aggressiveness and discovered that siRNA knock-down or inhibition of MTH1 with small molecules efficiently reduced viability of patient-derived GBM cultures. The effect of MTH1 loss on GBM viability was likely mediated through incorporation of oxidized nucleotides and subsequent DNA damage. We revealed that MTH1 inhibition targets GBM independent of aggressiveness as well as potently kills putative GBM stem cells in vitro. We used an orthotopic zebrafish model to confirm our results in vivo and light-sheet microscopy to follow the effect of MTH1 inhibition in GBM in real time.